Reference (author, year) | Region | Definition of CSU in weeks | Treatment | Number of CSU subjects undergoing IgE testing | Mean total IgE (kU/L) (SD) | Median Total IgE (kU/L) (IQR) | % of subjects previously on systemic corticosteroids (SC) | Number of antihistamine (AH) or systemic corticosteroid-free days | Range (kU/L) |
---|---|---|---|---|---|---|---|---|---|
Maurer, 2011 [68] | Germany | > 6 | Omalizumab | 27 | 211 (158) | – | – | – | – |
Placebo | 22 | 181 (136) | – | – | – | – | |||
Saini, 2011 [69] | USA and Germany | > 6 | Omalizumab or Placebo | 90 | 215 (432) | 88.5 | – | – | 2–3510 |
Nam, 2012 [70] | Korea | > 6 | Omalizumab | 26 | 248 (275) | – | 42.3 | – | – |
Kaplan, 2013 [71] | Various countries | > 6 | Omalizumab or Placebo | 335 | 159 (288) | 78 | 57.9 | 16 | 1–3050 |
Labrador-Horrillo, 2013 [72] | Spain | > 6 | Omalizumab | 107 | 133 | – | 77.3 | – | 2–1042 |
Maurer, 2013 [73] | Various countries | > 6 | Omalizumab or Placebo | 322 | 168 (232) | 78 | – | 30 (SC) | – |
Rottem 2014 [74] | Israel | > 6 | Omalizumab | 43 | 151 (255) | – | 88 | – | – |
Saini, 2015 [35] | Various countries | > 6 | Omalizumab or Placebo | 318 | – | 83 | – | 16 (SC) | 1–5000 |
Ensina, 2016 [75] | Brazil | – | Omalizumab | 27 | 159 | – | – | – | 0.2–774 |
Gomez-Vera, 2016 [25] | Mexico | > 6 | Omalizumab | 26 | – | 55.5 | – | – | 31.5–186 |
Wilches, 2016 [76] | Ecuador | > 6 | Omalizumab | 26 | 571 | – | – | – | 55–2500 |
Deza 2017 [77] | Spain | > 6 | Omalizumab | 47 | – | 116 | – | – | 42–277 |
Gericke, 2017 [78] | Germany | > 6 | Omalizumab | 56 | 205 (230) | – | – | – | – |
Jorg, 2017 [79] | Switzerland | > 6 | Omalizumab or Placebo | 30 | – | 137 (37.8–311) | – | AH, SC allowed | – |
Metz, 2017 [80] | Germany | > 6 | Omalizumab | 20 | 432 (1031) | – | – | 3 (AH), 30 (SC) | – |
Placebo | 10 | 184 (242) | – | – | 3 (AH), 30 (SC) | – | |||
Nettis, 2017 [81] | Italy | > 6 | Omalizumab | 290 | 235 (526) | 120 | 73.5 | Allowed (AH, SC) | 0–5237 |
Yang, 2017 [82] | Taiwan | > 6 | Omalizumab | 17 | 272.6 | – | 23.5 | – | 8.9–1510 |
Bulur, 2018 [83] | Turkey | > 6 | Omalizumab | 132 | 54.4 (150) | 65 | 62.1 | Allowed (AH, SC) | 7–978.9 |
Ertas, 2018 [84] | Turkey | > 6 | Omalizumab | 96 | – | 66.8 | – | – | 20.4–127 |
Ghazanfar, 2018 [85] | Denmark | > 6 | Omalizumab | 117 | 467 (1076) | – | – | Allowed (AH) | – |
Hide, 2018 [86] | Japan | > 6 | Omalizumab 150 mg | 71 | – | 335 | 26.5 | 30 | 15–2360 |
Omalizumab 300 mg | 73 | – | 428 | 37.1 | 20–4950 | ||||
Placebo | 73 | – | 414 | 36.1 | 0–5600 | ||||
Türk, 2018 [87] | Turkey | > 6 | Omalizumab | 25 | – | 226 | – | – | 56–340 |